Non-Executive Directors (which it is expected will be the applicable requirement for the reporting year 2018).
Companies and Groups (Accounts and Reports) (Amendment) Regulations 2013, are set out in the Remuneration Committee report.
— the performance of the Board, its Committees, and individual Directors are evaluated each year; and
— Reviews of the commercial progress made with the Group’s NIOX device, and, following the completion of the transaction relating  
The Board reviews the independence of its Non-Executive Directors each year.
The Company prepares a 10 year plan which was reviewed and approved by the Board at its meeting on 5 December 2017 .
The Board confirms that it has conducted a review of the Group’s risk management and internal controls systems, including financial, operational 
The Audit and Risk Committee reviews the Group’s financial controls on an annual basis and makes recommendations to the Board  
— The Group’s Senior Management Team, chaired by the Chief Executive Officer, is responsible for day to day operations.
— Promotional materials relating to the Group’s products are reviewed by a Promotional Review Committee and non-promotional materials  
On behalf of the Board I am pleased to present Circassia’s Audit and Risk Committee report for the year ended 31 December 2017 .
The Committee has responsibility for monitoring the integrity of the financial statements of the Group, and for reviewing the effectiveness  
CIR_AR17_back_v17.indd   49 25/04/2018   18:36 The Code provides that all members of the Audit and Risk Committee should be Independent Non-Executive Directors.
Following review of Group cash flows over a three year period to 31 December 2020, taking account of the Group’s current position and  
In making this statement, the Directors have considered the robustness of the Group, taking account of its current position, potential future 
The Group’s annual budget was approved by the Board at its December 2017 meeting and the 10 year plan was reviewed at the same meeting.
During the year, as is required by the Code, the Committee performed a detailed assessment of the principal risks faced by the Group and 
In summary, the Committee confirms that the Group has received an independent audit service in the year to 31 December 2017 and up  
The Company has complied during the financial year under review and up to the date of this report with the provisions of the Statutory Audit 
On behalf of the Board, I am pleased to present Circassia’s Nomination Committee report for the year ended 31 December 2017 .
On behalf of the Board, I am pleased to present Circassia’s Remuneration Committee report for the year ended 31 December 2017 .
The annual bonus plan for Executive Directors and management at Senior Vice President level includes an element being deferred into shares 
— Introduction of holding period requirement of two years for Executive Directors following exercise of PSP options
— ensuring that the remuneration of the Executive Directors and senior employees reflects performance and delivery of Shareholder value;
The amount shown relates to the gain, being the market value on date of vesting, less exercise price, on PSP 2014 share option awards that vested during the year.
It was explained in the Corporate governance section of this report that the Group granted certain Non-Executive Directors share options in the 
No Directors exercised share options in the financial year ended 31 December 2016.
In accordance with the Companies Act 2006, the Directors present their report together with the financial statements and the Independent 
In respect of the Annual report and accounts and financial statements for the year ended 31 December 2017
Company law requires the Directors to prepare Group and parent Company financial statements for each financial year.
statements and Directors Remuneration Report comply with the Companies Act 2006 and, as regards the Group financial statements,  
— the Strategic report includes a fair review of the development and performance of the business and the position of the Company and  
In our opinion, Circassia Pharmaceuticals plc’s group financial statements and parent company financial statements (the “financial statements”):
and the group’s and the parent company’s cash flows for the year then ended;
— have been prepared in accordance with the requirements of the Companies Act 2006 and, as regards the group financial statements,  
— Reporting entities where we performed audit procedures accounted for 99% of Group loss  
— The directors’ explanation on page 39 of the Annual Report as to how they have assessed the prospects of the group, over what period 
In preparing the financial statements, the directors are responsible for assessing the group’s and the parent company’s ability to continue 
— the parent company financial statements and the part of the Directors’ Remuneration Report to be audited are not in agreement with  
Though the Group continues to make losses, the Directors have reviewed the current and projected financial position of the Group,  
reporting period the Group revises its estimate of the number of options with non-market performance conditions that are expected to  
The average monthly number of persons (including Executive Directors) employed by the Group during the year was:
The details of Directors of the Group who received emoluments from the Group during the year are shown in the Annual report  
Key management personnel during the year included Directors (Executive and Non-Executive), the Chief Commercial Officer (to 2 March 2017), 
in the financial statements for the years ended 31 December 2017 and 2016 represents the credit receivable by the Group for the year  
CIR_AR17_back_v17.indd   108 25/04/2018   18:36 At 31 December 2017 , the Group has tax assets arising from tax credits in the United Kingdom for certain research and development expenditure 
CIR_AR17_back_v17.indd   116 25/04/2018   18:36 The Group and Company cash and cash equivalents and short-term deposits are held in the following currencies at 31 December:
During the year the Group awarded nil (2016: 156,035) deferred shares to Executive Directors as part of a deferred bonus for 2016.
the operating loss (administrative expenses line) for the year ended 31 December 2017 and £1.6 million has been offset against the Share 